Work

Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps5094

Authors: Toni K. Choueiri, Laurence Albiges, Li Fan, Rodolfo F. Perini, Naseem J. Zojwalla, Thomas Powles, Brian I. Rini

Institutions: Dana-Farber Cancer Institute, Institut Gustave Roussy, Merck & Co., Inc., Rahway, NJ, USA (United States), Barts Cancer Institute, Vanderbilt University Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3031189019

Cites:

Cited by: 12

Related to: 10